Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
暂无分享,去创建一个
Ludwig Kappos | Till Sprenger | Frederik Barkhof | Ernst-Wilhelm Radue | Jeffrey A. Cohen | F. Barkhof | L. Kappos | E. Radue | G. Francis | T. Sprenger | D. Häring | Gordon Francis | J. Bright | Dieter A. Häring | Ana de Vera | Philipp von Rosenstiel | Jeremy R. Bright | A. de Vera | P. von Rosenstiel | J. Cohen | Jeffrey A. Cohen | Philipp von Rosenstiel
[1] L. Kappos,et al. SWITCHING THERAPY TO FINGOLIMOD IMPROVES CLINICAL AND MRI OUTCOMES , 2014, Journal of Neurology Neurosurgery & Psychiatry.
[2] Ludwig Kappos,et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial , 2014, The Lancet Neurology.
[3] Jeffrey A. Cohen,et al. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis , 2014, Multiple sclerosis.
[4] Olivier Gout,et al. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis , 2014, Annals of neurology.
[5] Turi O. Dalaker,et al. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[6] H. Wiendl,et al. Clinical Relevance of Brain Volume Measures in Multiple Sclerosis , 2014, CNS Drugs.
[7] D. Arnold,et al. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis , 2014, Annals of neurology.
[8] S. Hussein,et al. Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years , 2013, American Journal of Neuroradiology.
[9] Elizabeth Fisher,et al. Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): Yes , 2013, Multiple sclerosis.
[10] Massimo Filippi,et al. Association between pathological and MRI findings in multiple sclerosis , 2012, The Lancet Neurology.
[11] Brian K. Rutt,et al. Deficient MWF mapping in multiple sclerosis using 3D whole-brain multi-component relaxation MRI , 2012, NeuroImage.
[12] P. Matthews,et al. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability , 2011, Multiple sclerosis.
[13] Jeffrey A. Cohen,et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study , 2011, The Lancet Neurology.
[14] M. Battaglini,et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes , 2010, Neurology.
[15] Ludwig Kappos,et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[16] Ludwig Kappos,et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[17] World Medical Association (WMA),et al. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects , 2009, Journal of the Indian Medical Association.
[18] Nicola De Stefano,et al. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS , 2009, Journal of the Neurological Sciences.
[19] Rohit Bakshi,et al. The measurement and clinical relevance of brain atrophy in multiple sclerosis , 2006, The Lancet Neurology.
[20] D. Paty,et al. Disability progression in multiple sclerosis is slower than previously reported , 2006, Neurology.
[21] Rohit Bakshi,et al. The relationship between whole brain volume and disability in multiple sclerosis: A comparison of normalized gray vs. white matter with misclassification correction , 2005, NeuroImage.
[22] Rohit Bakshi,et al. Central Nervous System Atrophy and Clinical Status in Multiple Sclerosis , 2004, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[23] P. M. Matthews,et al. Evidence of early cortical atrophy in MS , 2003, Neurology.
[24] J H Simon,et al. Eight-year follow-up study of brain atrophy in patients with MS , 2002, Neurology.
[25] Stephen M. Smith,et al. Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.
[26] David H. Miller,et al. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. , 2002, Brain : a journal of neurology.
[27] A J Thompson,et al. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.
[28] Terri L. Moore,et al. Regression Analysis by Example , 2001, Technometrics.
[29] Wolzt,et al. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.
[30] H. Adams,et al. Progressive cerebral atrophy in MS: A serial study using registered, volumetric MRI , 2000, Neurology.
[31] R. Rudick,et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.
[32] R. Guy,et al. International Conference on Harmonisation , 2014 .
[33] M. Mintun,et al. Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. , 2008, Archives of neurology.